Shots:
- LEO Pharma has initiated P-III (DELTA CARE 1) trial assessing Anzupgocream vs cream vehicle for the treatment of adults with mild to sev. lichen sclerosus (LS)
- DELTA CARE 1 will enroll ~652 adults with LS, starting with 300 female pts for dose selection, followed by evaluation vs vehicle in ~352 additional female & male pts across ~80–90 sites in the US, Canada, UK, Germany, France, Italy, Spain & Poland
- Anzupgois a topical pan-JAK inhibitor targeting all four JAKs involved in inflammation, with LEO Pharma holding global dermatology rights since 2014, excl. Japan, where Shionogi retains rights
Ref: Businesswire | Image: LEO Pharma | Press Release
Related News: LEO Pharma Reports the NMPA’s NDA Acceptance for Anzupgo (Delgocitinib) to Treat Chronic Hand Eczema (CHE)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
